Project description:Transcriptional profiling of human renal clear-cell carcinoma cells comparing control unexpressing MUC1 cells (82-F7 and 82-65 samples) with MUC1 overexpressing cells (83-2 and 83-5 samples)
Project description:Transcriptional profiling of human renal clear-cell carcinoma cells comparing control unexpressing MUC1 cells (82-F7 and 82-65 samples) with MUC1 overexpressing cells (83-2 and 83-5 samples) Goal was to determine the effect of MUC1 expression on global gene expression
Project description:Aquaporin-1 (AQP1) has been implicated in tumor progression, including cell migration, invasion, and angiogenesis in various cancers, but its specific role in renal clear cell carcinoma remains incompletely understood. To investigate the transcriptomic changes associated with AQP1 overexpression in renal cancer, we generated stable AQP1-overexpressing RENCA cells (a murine renal cell carcinoma cell line) and corresponding negative control cells using lentiviral transduction. Two weeks post-transduction, total RNA was extracted from three biological replicates per group and subjected to paired-end high-throughput RNA sequencing (RNA-seq). This dataset provides transcriptome profiles comparing AQP1-overexpressing RENCA cells to negative control cells, aiming to identify differentially expressed genes, pathways, and potential mechanisms by which AQP1 influences renal cancer biology. The data may facilitate further studies on AQP1 as a therapeutic target or biomarker in renal clear cell carcinoma.
Project description:To investigate the function of ANGPTL8 in clear cell renal cell carcinoma, Caki-1 cells overexpressing ANGPTL8 and ANGPTL8 knockout were established.
Project description:The aim of this study was to compare effect of everolimus on growth of different renal cell carcinoma (RCC) populations and develop design for experiments to measure the early response of everolimus in clear cell RCC (ccRCC) cell lines including renal cancer stem cells. Gene expression profiling using microarray was performed to determine the early response to everolimus after 3 days of treatment with optimizied concentration of drug in two ccRCC cell lines 1) parental clear cell renal cell carcinoma ccRCC-PCSC (HKPCSC -human parental kidney cancer stem cells) and 2) ccRCC-CSC - clear cell renal cell carcinoma -cancer stem cells (HKCSC - human kidney cancer stem cells).
